News | April 25, 2024
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)